Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Eloralintide

ENLIGHTEN-3

Eli Lilly · Phase 3 · Recruiting · Enrollment 800

NCT07369011

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Eloralintide (YSA1)n/rn/rn/rn/r
Placebo (YSA1)n/rn/rn/rn/r
Eloralintide (YSA2)n/rn/rn/rn/r
Placebo (YSA2)n/rn/rn/rn/r

Not shown

  • Eloralintide (YSA1): endpoint not reported
  • Placebo (YSA1): endpoint not reported
  • Eloralintide (YSA2): endpoint not reported
  • Placebo (YSA2): endpoint not reported